E

EPIMED GmbH | Berlin, Germany

Research site
(Unclaimed)
Location
Budapester Straße, 15-19, Berlin, Berlin, Germany
Site insights

Top conditions

HIV Infections (8 trials)

Infections (3 trials)

Acquired Immunodeficiency Syndrome (3 trials)

Hepatitis A (2 trials)

Immunologic Deficiency Syndromes (2 trials)

Top treatments

Ritonavir
Emtricitabine
Tipranavir
Elvitegravir
Tenofovir Disoproxil Fumarate
Tenofovir
Rilpivirine
Milvexian
Apricitabine
JNJ-73763989

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

1 of 16
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.

Enrolling
Ischemic Stroke; Ischemic Attack, Transient
Drug: Placebo
Drug: Milvexian

Trial sponsors

Gilead Sciences logo

Gilead Sciences (8 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems